Session Time: 12:30pm-2:00pm
Location: Research Hub - Kiosk 6
Disclosures: Lynne F Turner-Stokes, DM FRCP MBE: Ipsen: Honorarium
NIHR: Research Grant or Support
Objective: The ongoing ULIS-III study aims to describe real-life clinical practice and assess patient-centered goal attainment with integrated upper limb spasticity (ULS) management that includes repeated botulinum toxin A (BoNT-A) injections. This interim analysis evaluates BoNT-A reinjection intervals within a rehabilitation management setting during the first ULIS-III treatment cycle.
Design: Prospective observational study (NCT02454803) examining outcomes from repeated BoNT-A cycles over 2 years.
Setting: International multicenter study (interim analysis of patients from 53 secondary care centers in 14 countries).
Participants: Adults (≥18 years) with upper limb spasticity of various etiology.
Interventions: Patients are treated with BoNT-A per routine practice.
Main Outcome Measures: The primary outcome is Goal Attainment Scaling. In this interim analysis, we report on the duration of injection intervals. Differences between injection intervals were tested overall using a one-way ANOVA and, if ANOVA was significant, contrasts between abobotulinumtoxinA and other BoNT-A preparations were tested.
Results: Recruitment began in January 2015 and was completed in May 2017. Patients with data for ≥2 injections (N=640) were included in this analysis. Patients had a mean [95% CI] time between first and second injections of 186.1 [177.5, 194.8], 148.0 [134.2, 161.9], and 148.7 [131.4, 166.0] days for abobotulinumtoxinA (n=410), onabotulinumtoxinA (n=158), and incobotulinumtoxinA (n=72), respectively. The mean time between injections was significantly longer for those patients treated with abobotulinumtoxinA than other BoNT-As (ANOVA; P<.001).
Conclusions: Preliminary real-life ULIS-III injection-interval data show that patients treated with abobotulinumtoxinA had, on average, a significantly longer injection interval than patients treated with other BoNT-As. Longer injection intervals may suggest longer lasting symptom relief between injections and less patient and carer burden. Final ULIS-III data will provide additional clarity to these preliminary analyses.
Level of Evidence: Level II
To cite this abstract in AMA style:Turner-Stokes LF, Ashford S, Fheodoroff K, Maisonobe P, Lysandropoulos A, Jacinto J. Time to Retreatment with Botulinum Toxin A in Upper Limb Spasticity Management: An Interim Analysis from the Upper Limb International Spasticity (ULIS)-III Study [abstract]. PM R. 2019; 11(S2)(suppl 2). https://pmrjabstracts.org/abstract/time-to-retreatment-with-botulinum-toxin-a-in-upper-limb-spasticity-management-an-interim-analysis-from-the-upper-limb-international-spasticity-ulis-iii-study/. Accessed October 23, 2021.
« Back to AAPM&R Annual Assembly 2019
PM&R Meeting Abstracts - https://pmrjabstracts.org/abstract/time-to-retreatment-with-botulinum-toxin-a-in-upper-limb-spasticity-management-an-interim-analysis-from-the-upper-limb-international-spasticity-ulis-iii-study/